Trademark Overview
On Thursday, September 28, 2023, a trademark application was filed for CRST with the United States Patent and Trademark Office. The USPTO has given the CRST trademark a serial number of 98201920. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Tuesday, April 30, 2024. This trademark is owned by ReNAgade Therapeutics Management, Inc.. The CRST trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:
Enzymes, nucleic acid molecules, and compounds/agents for modifying small RNAs with targeting agents for medical use, namely, use of the modified small RNAs in the gene editing industry; pharmaceutical preparations and therapeutic agents, namely, for gene therapy and mRNA regulation; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation
Chemical and biological agents for scientific and research use, namely, for the modification of small RNAs with targeting agents and for regulating expression and/or levels of mRNA with the modified RNAs; enzymes for scientific and research purposes; enzyme preparations for use in modifying small RNAs and for use of modified small RNAs in the gene editing industry; Nucleic acid sequences for other than medical and veterinary purposes
Research and development in the field of technology and engineering RNAs with targeting agents for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of RNA with targeting agents, namely, developing molecular and cellular biology reagents, techniques, and assays for use in the gene editing industry